Impact of New Anthropometric Indices on Outcomes After Cardiac Surgery

Obesity is associated with a number of risk factors for cardiovascular disease. Body mass index (BMI) is the most commonly recommended and used anthropometric measure to classify general obesity in clinical and epidemiological studies. It is widely accepted that obesity increases the risk of heart disease and is thought to be a risk factor for adverse outcomes after cardiac surgery. However, recent studies show paradoxical results, wherein obese patients can experience fewer adverse events and lower mortality than patients with normal-low body mass index(BMI) . The discriminative capacity of BMI has been criticized because it cannot distinguish muscle mass from fat mass, or reflect fat distribution . Alternatively, abdominal obesity indices, such as waist circumference (WC) and waist-to-height ratio (WHtR), have been suggested to be better predictor of cardiometabolic abnormalities because they modulate the limitation of BMI. However, they were insufficient in studies.For this reason, scientists turned to find a new anthropometric formula that could better detect obesity-related mortality and morbidity and they developed 2 new methods. Body Shape İndex (ABSI) is calculated using waist circumference, BMI and height parameters. Body Roundness İndex (BRI) is calculated using waist circumference and height parameters. These new indices may reflect visceral adiposity and strongly predict cardiovascular risk, postsurgical outcomes and resource utilisation.

Study Overview

• Status: Not yet recruiting
• Conditions: Coronary Artery Disease; Cardiac Surgery; Anthropometry; Cardiometabolic Risk Factors; Cardiac Anesthesia

• Study Type: Observational
• Enrollment (Anticipated): 240

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients over the age of 18 who have undergone open heart surgery

Description

Inclusion Criteria:

• open heart surgery
• voluntary patients

Exclusion Criteria:

• emergency surgery
• off-pump or robotic surgery
• surgery requiring deep hypothermic circulatory arrest
• reluctant patients

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
mortality	Number of death at 30 days after surgery	within 30 days of the procedure
postoperative stroke	Number of patients with postoperative stroke	within 30 days of the procedure
cardiac arrest	number of patients with cardiac arrest	within 30 days of the procedure
new atrial fibrillation/flutter	Number of Partients with new atrial fibrillation/flutter	within 30 days of the procedure
permanent rhythm device insertion	Number of Patients requiring insertion of a permanent device	within 30 days of the procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
prolonged ventilation	number of patients experiencing prolonged postoperative pulmonary ventilation (>24 hours)	within 30 days of the procedure
sepsis /deep sternal infection	number of patients with sepsis, deep sternal wound infection or mediastinitis	within 30 days of the procedure
pulmonary complications	number of patients with pneumonia or pleural effusion	within 30 days of the procedure
renal failure / renal dialysis	number of patient with acute renal failure or worsening renal function result	within 30 days of the procedure
total intensive care unit (ICU) hours	total intensive care unit (ICU) hours	within 30 days of the procedure
intensive care unit (ICU) readmissions	number of patients with intensive care unit readmission	within 30 days of the procedure

Collaborators and Investigators

• Sponsor: TC Erciyes University

Study record dates

Study Major Dates

• Study Start (Anticipated): July 27, 2022
• Primary Completion (Anticipated): October 1, 2022
• Study Completion (Anticipated): November 1, 2022

Study Registration Dates

• First Submitted: May 2, 2022
• First Submitted That Met QC Criteria: May 30, 2022
• First Posted (Actual): June 3, 2022

Study Record Updates

• Last Update Posted (Actual): July 28, 2022
• Last Update Submitted That Met QC Criteria: July 26, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Coronary Artery Disease
• Other Study ID Numbers: 2022/02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No